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Abstract
Background: This study compared the clinical and functional outcomes of patients initially treated with observation or
medical treatment with those of patients treated with local treatment (surgery alone or surgery with adjuvant
radiotherapy) to confirm whether observation or medical treatment is an appropriate first-line management approach
for patients with desmoid tumors.
Methods: We retrospectively reviewed the medical records of 99 patients with histologically confirmed primary
desmoid tumors treated between 1978 and 2018. The median follow-up period was 57months. We evaluated event-
free survival, defined as the time interval from the date of initial diagnosis to the date of specific change in treatment
strategy or recurrence or the last follow-up.
Results: An event (specific change in treatment strategy or recurrence) occurred in 28 patients (28.3%). No significant
difference in event-free survival was found between the first-line observation/medical treatment and local treatment
groups (p = 0.509). The median Musculoskeletal Tumor Society score of the patients treated with first-line local
treatment was 29 (interquartile range [IQR], 23–30), whereas that of the patients managed with first-line observation or
medical treatment was 21 (IQR, 19–29.5). First-line observation or medical treatment was more frequently chosen for
larger tumors (p = 0.045). In the patients treated with local treatment, local recurrence was not related to the surgical
margin (p = 0.976).
Conclusion: Upfront surgery is not advantageous compared to more conservative treatments such as observation or
medical treatment for patients with desmoid tumors.
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Background
A desmoid tumor (DT) or aggressive fibromatosis is a
“clonal fibroblastic proliferation that arises in the deep
soft tissues and is characterized by infiltrative growth
and a tendency toward local recurrence but an inability
to metastasize even though it may be multifocal in the
same limb or body part” [1]. Before the 2000s, surgery
with microscopically negative margins was considered
the standard of care for patients with DT, which is simi-
lar to the treatment approach for soft tissue sarcomas of
the extremities owing to the infiltrative growth pattern
of DT [2]. However, DT resection often leads to sub-
stantial function impairment and cosmetic alterations in
patients affected by an otherwise benign disease, without
avoiding the high risk of local recurrence despite the
wide margins of resection [2]. For this reason, a shift to-
ward more conservative management has been intro-
duced recently [3]. In accordance with this approach, an
observation alone strategy has been recommended as
the first-line approach in newly diagnosed patients, re-
serving chemotherapy, a tyrosine kinase inhibitor, radi-
ation, and surgical treatment for cases of disease
progression [4]. According to the recent consensus rec-
ommendations from the Desmoid Tumor Working
Group, management of asymptomatic patients with ini-
tial observation, independent of tumor site and size, can
be proposed [5]. An earlier decision toward an active
treatment is needed for DTs located close to critical
structures (e. g., mesenteric or head and neck), and for
sites other than the abdominal wall, medical treatment
should be considered as the first treatment option in
case of progression [5]. In addition, because DT is a
benign and symptomatic tumor, studies focusing on pa-
tient outcomes in terms of symptoms and function are
needed [6].
Our objective was to investigate whether observation
or medical treatment is an appropriate first-line manage-
ment approach for patients with DT. Therefore, we per-
formed a retrospective study to compare the clinical and
functional outcomes of initial observation or medical
treatment, with initial local treatment (surgery with or
without radiotherapy).
Methods
We retrospectively reviewed the medical files of 253 pa-
tients with histologically confirmed DT who were treated
at the senior author’s institution between 1978 and 2018.
As intra-abdominal DT is a completely different disease
from extraperitoneal DT with regard to various factors
(associated with familial adenomatous polyposis, treat-
ment strategy, and prognosis), patients with intra-
abdominal DT were excluded from this study [7]. The
management of DT has evolved over the decades. Before
2010, we treated DTs with surgery. Recently, we observed
patients with newly diagnosed DT following current prac-
tice paradigms, that is, observation as the first-line ap-
proach. Once patients showed clinical progression or
symptoms, we switched to local or medical treatment. We
evaluated the patients’ characteristics, DT size, treatment
approaches, surgical margins, and patient outcomes (Ta-
bles 1 and 2). Thirty-seven patients with < 12months of
follow-up, 113 patients with missing data, and 4 patients
referred for tumor recurrence were excluded. The
remaining 99 patients were included in this study for
further analysis. The characteristics of the included and
excluded patients are shown in the Appendix. The median
follow-up period was 57months (interquartile range
[IQR], 33–86months). As first-line management, local
treatment was performed in 60 patients (45 patients re-
ceived surgery alone, and 15 patients received surgery with
adjuvant radiotherapy) and observation (16 patients) or
medical treatment (16 patients received low-dose chemo-
therapy, and 7 patients received non-steroidal anti-
inflammatory drugs [NSAIDs] alone or a combination of
NSAIDs and anti-hormonal therapy [tamoxifen]) was
chosen for 39 patients. All patient data were retrieved
from the patients’ medical records. All the patients pro-
vided written informed consent for the inclusion of their
data in this study. Institutional review board/ethics com-
mittee approval was not considered necessary for retro-
spective studies at the senior author’s institution.
We analyzed the prognostic values of age at presenta-
tion, sex, DT site and size, previous surgery or trauma in
the area of the primary tumor, biopsy technique, initial
treatment, year of diagnosis, adjuvant radiotherapy, and
surgical margin. We divided the patients into 2 groups
according to the tumor site because tumors in the ex-
tremities were reported to be associated with a higher
local recurrence rate [8].
DT size was defined as the greatest dimension on im-
aging before any treatment. Low-dose chemotherapy
with methotrexate at a dose of 30 mg/m2 plus vinblast-
ine at a dose of 6 mg/m2, as previously reported [9], was
administered to 27 patients for a median period of 12
months (IQR, 6–15months) in the overall therapeutic
process. Six (22.2%) of the patients required repeated
low-dose chemotherapy. NSAIDs were administered to
17 patients for a median period of 13 months (IQR, 4.5–
25months); tyrosine kinase inhibitor, to one patient for
12 months; and a combination of NSAIDs and anti-
hormonal therapy, to 12 patients for a median period of
14 months (IQR, 4.5–22.5 months) in the overall thera-
peutic process.
Routine clinical and imaging follow-up evaluations
were performed at 8 and 12 weeks, and then every 3
months for the first year, followed by every 6months for
the next 4 years and yearly thereafter. Response to med-
ical treatment was assessed on the basis of the DT size
Tsukamoto et al. BMC Musculoskeletal Disorders           (2021) 22:12 Page 2 of 10
reduction, along with computed tomography (CT) or
magnetic resonance imaging (MRI) for the best re-
sponse, and was rated as “complete response,” “partial
response,” “stable disease,” or “progressive disease” ac-
cording to the modified Response Evaluation Criteria in
Solid Tumors (version 1.1), which assesses the tumor ex-
tent on the basis of the sum of the longest diameter of
all target lesions [10]. Functional scores according to the
Musculoskeletal Tumor Society (MSTS) scoring system
were collected for patients with extremity DTs when
possible [11]. The MSTS score was based on 3 general
factors (pain, function, and emotional acceptance) and 3
lower limb factors (use of supports, ability to walk, and
gait) [11].
The chi-square or Fisher exact test was used to evalu-
ate the association between categorical variables, as ap-
propriate. The differences between the independent
continuous variables were statistically analyzed using the
Mann-Whitney U test for nonparametric analyses.
Event-free survival was defined as the time interval from
the date of initial diagnosis to the date of specific change
in treatment strategy or recurrence or the last follow-up.
The specific change in treatment strategy was defined as
the change from observation or NSAIDs/anti-hormonal
therapy to low-dose chemotherapy or surgery, or the
change from low-dose chemotherapy to surgery.
Recurrence-free survival was defined as the time interval
from the date of initial diagnosis to the date of




Initial treatment P value
Local treatment (n = 60, 60.6%) Observation/medical treatment (n = 39, 39.4%)
Age at diagnosis (years)
Median 38.2 39.4 36.1 0.670
IQR 25.4–47.7 25.5–50.8 23.8–44.3
Sex
Male 37, 37.4% 23, 38.3% 14, 35.9% 0.806
Female 62, 62.6% 37, 61.7% 25, 64.1%
Tumor site
Abdominal wall 4, 4.0% 2, 3.3% 2, 5.1% 0.901c
Upper extremity 10, 10.1% 9, 15.0% 1, 2.6%
Lower extremity 39, 39.4% 21, 35.0% 18, 46.2%
Girdle 31, 31.3% 20, 33.3% 11, 28.2%
Head and neck 6, 6.1% 2, 3.3% 4, 10.3%
Chest wall 9, 9.1% 6, 10.0% 3, 7.7%
Tumor size (cm)
Median 8 7 9 0.045a
IQR 5–11 5–10 6–13
Clinical presentation
Mass 42, 42.4% 23, 38.3% 19, 48.7% 0.308d
Pain 7, 7.1% 3, 5.0% 4, 10.3%
Mass + Pain 46, 46.5% 33, 55.0% 13, 33.3%
Functional impairment 2, 2.0% 0 2, 5.1%
Functional impairment + Pain 2, 2.0% 1, 1.7% 1, 2.6%
Previous surgery or trauma at the site of the primary tumor
Yes 14, 14.1% 9, 15.0% 5, 12.8% 0.721b
No 85, 85.9% 51, 85.0% 34, 87.2%
Year of diagnosis
1999–2009 61, 61.6% 48, 80.0% 13, 33.3% < 0.001a
2010–2018 38, 38.4% 12, 20.0% 26, 66.7%
IQR interquartile range. aThe difference was significant. bThe Fisher exact test was used. cComparison of extremity and non-extremity. dComparison of mass alone
and the others
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recurrence or the last follow-up. Event- and recurrence-
free survival were evaluated with the Kaplan-Meier sur-
vival analysis, and survival curves were compared using
a log-rank test. A p value < 0.05 was considered statisti-
cally significant. Analyses were performed using IBM
SPSS version 25.0 (IBM Co., Armonk, NY, USA) and
JMP 14 (SAS Institute Inc., Cary, NC, USA).
Results
Overall, events (specific change in treatment strategy or
recurrence) occurred in 28 patients (28.3%), and none of
the patients died of disease. The univariate analysis re-
vealed that male sex had a significant association with
unfavorable event-free survival (p = 0.024; Table 3). No
significant difference in event-free survival was observed
between the first-line observation/medical treatment and
local treatment groups (p = 0.509; Table 3, Fig. 1).
First-line observation or medical treatment was more
frequently chosen for larger tumors (p = 0.045) and
between 2010 and 2018 (p < 0.001; Table 1). The num-
ber of surgical operations in the overall therapeutic
process was higher in the first-line local treatment group
than in the first-line observation or medical treatment
group (p < 0.001; Table 2). The number of patients who
received low-dose chemotherapy in the overall thera-
peutic process was significantly higher in the first-line





Local treatment (n = 60, 60.6%) Observation/medical treatment (n = 39, 39.4%)
Biopsy
Core needle biopsy 70, 70.7% 38, 63.3% 32, 82.1%
Open biopsy 29, 29.3% 22, 36.7% 7, 17.9%
Total number of surgeries
Median 1 1 0
IQR 0–1 1–2 0–0
NSAIDs
No 82, 82.8% 60, 100.0% 22, 56.4%
Yes 17, 17.2% 0 17, 43.6%
Tyrosine kinase inhibitor
No 98, 99.0% 60, 100.0% 38, 97.4%
Yes 1, 1.0% 0 1, 2.6%
Anti-hormonal therapy + NSAIDs
No 87, 87.9% 59, 98.3% 28, 71.8%
Yes 12, 12.1% 1, 1.7% 11, 28.2%
Low-dose chemotherapy
No 72, 72.7% 56, 93.3% 16, 41.0%
Yes 27, 27.3% 4, 6.7% 23, 59.0%
Follow up period (months)
Median 57 58.5 55
IQR 33–86 35–96 27–85
Event
No 71, 71.7% 41, 68.3% 30, 76.9%
Yes 28, 28.3% 19, 31.7% 9, 23.1%
Interval between the diagnosis and event
Median 18 19 13
IQR 9–32 9–36 9–24
MSTS score
Median 26 29 21
IQR 21–30 23–30 19–29.5
IQR interquartile range, NSAIDs non-steroidal anti-inflammatory drugs, MSTS Musculoskeletal Tumor Society
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observation or medical treatment group than in the
first-line local treatment group (p < 0.001; Table 2). The
median MSTS score of the 39 patients was 26 (IQR, 21–
30). The median MSTS score of the 23 patients treated
with first-line local treatment was 29 (IQR, 23–30),
whereas that of the 16 patients managed with first-line
observation or medical treatment was 21 (IQR, 19–29.5).
The univariate analysis for the patients initially treated
with local treatment revealed that male sex was signifi-
cantly associated with unfavorable recurrence-free sur-
vival (p = 0.021; Table 4). The surgical margins of the
initial surgery in the surgery alone group were R0
(microscopic complete resection) in 23 patients, R1
(microscopic incomplete resection) in 16 patients, and
R2 (macroscopic incomplete resection) in 6 patients.
The surgical margins in the initial surgery in the “sur-
gery with adjuvant radiotherapy” group were R0 in 6
patients, R1 in 8 patients, and R2 in 1 patient. The
recurrence-free survival rates were not significantly
different according to the surgical margin of the initial
surgery and the presence of adjuvant radiotherapy in the
univariate analysis (Table 4). The univariate analysis for
the patients initially managed with observation or med-
ical treatment revealed that none of the 8 variables (age,
sex, tumor site, tumor size, previous surgery or trauma
at the site of the primary tumor, year of diagnosis, bi-
opsy, and initial treatment [observation+/−tamoxifen or
NSAIDs vs. low-dose chemotherapy]) were significantly
associated with event-free survival.
Among the patients who received low-dose chemo-
therapy in the overall therapeutic process, 3 (11.1%) ex-
perienced a partial response; 23 (85.1%), stable disease;
and 1 (3.7%), disease progression. Among the patients
treated with NSAIDs in the overall therapeutic process,
11 (64.7%) experienced stable disease and 6 (35.3%) ex-
perienced disease progression. The patient treated with a
tyrosine kinase inhibitor exhibited a stable disease.
Among the patients treated with combined NSAIDs and
anti-hormonal therapy in the overall therapeutic process,
9 (75.0%) experienced stable disease and 3 (25.0%) dis-
played disease progression. Among the 16 patients who
were managed with first-line observation, 7 (43.8%)
Table 3 Univariate predictors of event-free survival
Variable Patients (n) 5-year event-free survival (95% CI, %) P value
Age at diagnosis (years)
≤30 35 70.2 (52.8–83.3) 0.764
> 30 64 69.8 (56.3–80.6)
Sex
Male 37 56.3 (39.3–71.9) 0.024a
Female 62 77.8 (64.4–87.1)
Tumor site
Extremities 49 66.9 (51.8–79.1) 0.522
Non-extremities 50 73.1 (58.0–84.3)
Tumor size (cm)
≤5 25 82.8 (61.8–93.5) 0.345
5<, < 10 37 71.3 (54.2–83.9)
≥10 37 60.1 (41.9–75.9)
Previous surgery or trauma at the site of the primary tumor
Yes 14 77.1 (47.9–92.5) 0.998
No 85 68.8 (57.4–78.3)
Year of diagnosis
1999–2009 61 64.9 (51.1–76.6) 0.372
2010–2018 38 78.8 (63.0–89.0)
Biopsy
Core needle biopsy 70 72.9 (60.4–82.6) 0.190
Open biopsy 29 63.2 (43.7–79.2)
Initial treatment
Local treatment 60 66.8 (53.0–78.2) 0.509
Observation/medical treatment 39 75.2 (58.6–86.7)
aStatistically significant
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experienced a disease progression; 2 (12.5%), stable dis-
ease; and 7 (43.8%), spontaneous regression.
Discussion
Our results showed similar event-free survival between
observation or medical treatment and local treatment as
the first-line approach. The published studies regarding
active surveillance for DT are summarized in Table 5 [3,
12–25]. Of patients under active surveillance, 4–37%
spontaneously regressed, 17–92% had stable disease, and
4–59% had tumor progression [3, 12–25]. Kito et al. [26]
performed a systematic review comparing surgery and
active surveillance. They reported that the exacerbation
rate (exacerbation; recurrence after surgery or progres-
sive disease after active surveillance) was significantly
higher in the surgery group (odds ratio, 1.32; 95% confi-
dence interval [CI], 1.01–1.73; p = 0.05). Thus, our re-
sults confirmed that the use of first-line observation or
medical treatment is appropriate for DT. A recent joint
global consensus-based guideline from the Desmoid
Tumor Working Group recommended that first-line
treatment should start with a plan for active surveillance
[5]. Indications for active treatment include pain, with or
without radiological evidence of progression, functional
symptoms, or patient request [27]. According to a recent
systematic literature review of active surveillance for pa-
tients with DTs, the median follow-up time of the pa-
tients was reported in 12 studies and ranged from 8 to
73months [28]. In the case of subsequent progression or
a significant increase in symptom burden, a decision
toward treatment may be considered and assessed with
at least 3 further assessments and possibly not before 1
year after the initial diagnosis [29].
This study showed poor extremity functional out-
comes in the first-line observation/medical treatment
group. However, larger tumors were more frequently
managed with first-line observation or medical treat-
ment, which may explain the reason for the poor ex-
tremity functional outcome in the first-line observation/
medical treatment group. Newman et al. [6] reported
that the Patient-reported Outcomes Measurement Infor-
mation System function scores were lowest among pa-
tients who underwent ≥2 surgical interventions and
among those treated with surgery and radiation at any
time. Duhil de Benaze et al. [30] analyzed the long-term
quality of life of pediatric patients with DT by using the
Child Health Questionnaire. They did not find any dif-
ference in the quality-of-life scores between patients
who underwent first-line observation and those who re-
ceived more aggressive therapies (surgery or chemother-
apy). Pain is not strictly correlated with DT progression;
some stable DT may be painful, while some progressive
DT may not be painful; sometimes, pain can be the con-
sequence of previous locoregional treatments rather than
the disease [31]. Therefore, unless the tumors are
located in sites at risk of potentially life-threatening con-
ditions, the most meaningful end point for evaluating
the effectiveness of treatment strategies for DTs may be
the impact on patient symptoms and function, rather
than the traditional oncologic metrics such as local
Fig. 1 Kaplan-Meier analysis of event-free survival according to initial treatment. The shading surrounding the curves represents the 95% confidence interval
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recurrence and disease progression on imaging [6, 23].
Thus, in the future, prospective data on function and
quality of life must be collected from a larger cohort of
patients with DTs.
In this study, observation or medical treatment was
more frequently selected for larger tumors. Primary re-
section should be considered for small tumors, and med-
ical therapy should be considered for large tumors [30].
Moreover, in this study, the patients treated with first-
line local treatment needed less low-dose chemotherapy
in their overall treatment than those managed with first-
line observation or medical treatment. Duhil de Benaze
et al. [30] and Sparber-Sauer et al. [32] reported the
same results as ours. As first-line local treatments were
more frequently selected for smaller tumors, low-dose
chemotherapy might be less frequently indicated.
Our study shows that male sex had a significant asso-
ciation with unfavorable event- and recurrence-free sur-
vival. Most previous studies reported no association
between sex and outcome [14, 16, 19, 21, 23, 33–35],
while Huang et al. [36] reported that male sex was a pre-
dictor of local recurrence in the univariate analysis.
Hong et al. [37] reported that testosterone regulates β-
catenin protein levels and proliferation rates in DT.
They found the possibility of therapeutic use of testos-
terone blockade in DT.
Our results showed that neither surgical margin nor ad-
juvant radiotherapy affected local recurrence. In 2017,
Janssen et al. [38] performed a meta-analysis of the influ-
ence of surgical margins and adjuvant radiotherapy on
local recurrence after resection of sporadic DT. In patients
treated with surgical resection alone, the risk of local
Table 4 Univariate predictors of recurrence-free survival in patients initially treated with local treatment
Variable Patients (n) 5-year recurrence-free survival (95% CI, %) P value
Age at diagnosis (years)
≤30 22 72.4 (50.6–87.1) 0.711
> 30 38 62.8 (44.6–78.0)
Sex
Male 23 50.2 (30.1–70.2) 0.021a
Female 37 76.9 (58.4–88.8)
Tumor site
Extremities 30 70.2 (50.4–84.6) 0.571
Non-extremities 30 63.0 (43.3–79.2)
Tumor size (cm)
≤5 17 86.9 (59.6–96.7) 0.295
5<, < 10 25 62.1 (41.5–79.1)
≥10 18 55.2 (29.2–78.6)
Previous surgery or trauma at the site of the primary tumor
Yes 9 77.8 (42.1–94.4) 0.936
No 51 65.0 (49.9–91.7)
Year of diagnosis
1999–2009 48 65.1 (49.5–78.0) 0.750
2010–2018 12 75.0 (44.8–91.7)
Biopsy
Core needle biopsy 38 70.4 (52.8–83.5) 0.251
Open biopsy 22 60.6 (38.2–79.2)
Adjuvant radiotherapy
No 45 73.0 (57.2–84.5) 0.110
Yes 15 48.6 (23.8–74.1)
Surgical margin
R0 29 67.7 (48.4–82.4) 0.976
R1/2 31 66.4 (46.5–81.8)
aStatistically significant. Macroscopic incomplete resection, R2; microscopic incomplete resection, R1; microscopic complete resection, R0
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recurrence was almost twofold higher than that in patients
with microscopically positive resection margins (risk ratio
[RR], 1.78; 95% CI, 1.40–2.26) [38]. Adjuvant radiotherapy
after surgery with negative margins had no detectable
benefit on recurrence [38]. By contrast, after incomplete
surgical resection, adjuvant radiotherapy improved the re-
currence rates both in the patients with primary tumors
(RR, 1.54; 95% CI, 1.05–2.27) and in those with recurrent
DF (RR, 1.60; 95% CI, 1.12–2.28) [38]. Contrary to our re-
sults, evidence supports the effect of negative margins and
adjuvant radiotherapy on local recurrence [38]. Turner
et al. [24] suggested that negative margins should be the
goal, but should not be pursued at the expense of sig-
nificant functional loss. They suggested one additional
consideration, namely tumor behavior [24]. Any re-
sidual from an aggressive tumor should be presumed
to be at high risk of regrowth and that negative mar-
gins are therefore more important in this group [24].
On the other hand, more indolent disease may shift
the balance in favor of minimizing surgical morbidity
in cases that still require surgery [24].
Our study has several limitations. First, it was a retro-
spective study with inherent limitations and risk of selec-
tion bias. Smaller tumors were excluded from this study
(Appendix). Second, the tumor size was not uniform
among the first-line treatment groups. This may have af-
fected the event-free survival or functional outcome.
Third, a power analysis was not performed, and a risk of
type II error due to the small sample size was present. If
an adequate number of patients is gathered in the future,
significant differences may appear regarding the other
variables in this study. Forth, we were not able to com-
pare the event-free survival between first-line observa-
tion and medical treatment groups due to the small
sample size. Kasper et al. stated that a stepwise therapy
escalation from an initial, less toxic treatment including
observation to more toxic agents seems reasonable for
progressive DTs [29]. These limitations should be con-
sidered in the analysis of our study results.
Conclusions
Upfront surgery is not advantageous compared to more
conservative treatments such as observation or medical
treatment for patients with desmoid tumors.
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